{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T13:49:07Z","timestamp":1782913747435,"version":"3.54.5"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,3,1]]},"DOI":"10.7759\/cureus.79881","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T15:28:11Z","timestamp":1740842891000},"source":"Crossref","is-referenced-by-count":7,"title":["Blood-Based \u03b2-Amyloid and Phosphorylated Tau (p-Tau) Biomarkers in Alzheimer\u2019s Disease: A Systematic Review of Their Diagnostic Potential"],"prefix":"10.7759","author":[{"given":"Meghana","family":"Dasari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel Abraham","family":"Kurian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumanth","family":"Gundraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aishwarya","family":"Raparthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rooth V","family":"Medapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2024.0286","article-title":"Amyloid-\u03b2 and phosphorylated tau are the key biomarkers and predictors of Alzheimer's disease","author":"Pradeepkiran JA","year":"2024","unstructured":"Pradeepkiran JA, Baig J, Islam MA, Kshirsagar S, Reddy PH. Amyloid-\u03b2 and phosphorylated tau are the key biomarkers and predictors of Alzheimer's disease. Aging Dis. 2024, 10.14336\/AD.2024.0286","journal-title":"Aging Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13332","article-title":"Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease","volume":"290","author":"Alawode DO","year":"2021","unstructured":"Alawode DO, Heslegrave AJ, Ashton NJ, et al.. Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. J Intern Med. 2021, 290:583-601. 10.1111\/joim.13332","journal-title":"J Intern Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-021-05253-y","article-title":"The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers","volume":"48","author":"Ashton NJ","year":"2021","unstructured":"Ashton NJ, Leuzy A, Karikari TK, et al.. The validation status of blood biomarkers of amyloid and phospho-tau assessed with the 5-phase development framework for AD biomarkers. Eur J Nucl Med Mol Imaging. 2021, 48:2140-56. 10.1007\/s00259-021-05253-y","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1515\/cclm-2023-1434","article-title":"Blood-based biomarkers in Alzheimer's disease\u00a0- moving towards a new era of diagnostics","volume":"62","author":"Arslan B","year":"2024","unstructured":"Arslan B, Zetterberg H, Ashton NJ. Blood-based biomarkers in Alzheimer's disease\u00a0- moving towards a new era of diagnostics. Clin Chem Lab Med. 2024, 62:1063-9. 10.1515\/cclm-2023-1434","journal-title":"Clin Chem Lab Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/joim.12816","article-title":"Biomarkers for Alzheimer's disease: current status and prospects for the future","volume":"284","author":"Blennow K","year":"2018","unstructured":"Blennow K, Zetterberg H. Biomarkers for Alzheimer's disease: current status and prospects for the future. J Intern Med. 2018, 284:643-63. 10.1111\/joim.12816","journal-title":"J Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-170773","article-title":"The past and the future of Alzheimer's disease fluid biomarkers","volume":"62","author":"Blennow K","year":"2018","unstructured":"Blennow K, Zetterberg H. The past and the future of Alzheimer's disease fluid biomarkers. J Alzheimers Dis. 2018, 62:1125-40. 10.3233\/JAD-170773","journal-title":"J Alzheimers Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.942629","article-title":"Plasma tau proteins for the diagnosis of mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis","volume":"14","author":"Chen L","year":"2022","unstructured":"Chen L, Niu X, Wang Y, Lv S, Zhou X, Yang Z, Peng D. Plasma tau proteins for the diagnosis of mild cognitive impairment and Alzheimer's disease: A systematic review and meta-analysis. Front Aging Neurosci. 2022, 14:942629. 10.3389\/fnagi.2022.942629","journal-title":"Front Aging Neurosci"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252010911","article-title":"Blood-based biomarkers in Alzheimer's disease: advancing non-invasive diagnostics and prognostics","volume":"25","author":"Dhauria M","year":"2024","unstructured":"Dhauria M, Mondal R, Deb S, Shome G, Chowdhury D, Sarkar S, Benito-Le\u00f3n J. Blood-based biomarkers in Alzheimer's disease: advancing non-invasive diagnostics and prognostics. Int J Mol Sci. 2024, 25:10.3390\/ijms252010911","journal-title":"Int J Mol Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7326\/M19-3888","article-title":"Accuracy of biomarker testing for neuropathologically defined Alzheimer disease in older adults with dementia","volume":"172","author":"Fink HA","year":"2020","unstructured":"Fink HA, Linskens EJ, Silverman PC, et al.. Accuracy of biomarker testing for neuropathologically defined Alzheimer disease in older adults with dementia. Ann Intern Med. 2020, 172:669-77. 10.7326\/M19-3888","journal-title":"Ann Intern Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1097\/EJA.0000000000001933","article-title":"Associations between Alzheimer's disease biomarkers and postoperative delirium or cognitive dysfunction: a meta-analysis and trial sequential analysis of prospective clinical trials","volume":"41","author":"Geng J","year":"2024","unstructured":"Geng J, Zhang Y, Chen H, Shi H, Wu Z, Chen J, Luo F. Associations between Alzheimer's disease biomarkers and postoperative delirium or cognitive dysfunction: a meta-analysis and trial sequential analysis of prospective clinical trials. Eur J Anaesthesiol. 2024, 41:234-44. 10.1097\/EJA.0000000000001933","journal-title":"Eur J Anaesthesiol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/biom14010093","article-title":"Blood biomarkers of Alzheimer's disease and cognition: a literature review","volume":"14","author":"Garcia-Escobar G","year":"2024","unstructured":"Garcia-Escobar G, Manero RM, Fern\u00e1ndez-Lebrero A, et al.. Blood biomarkers of Alzheimer's disease and cognition: a literature review. Biomolecules. 2024, 14:10.3390\/biom14010093","journal-title":"Biomolecules"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2010.09.007","article-title":"Identifying and validating biomarkers for Alzheimer's disease","volume":"29","author":"Humpel C","year":"2011","unstructured":"Humpel C. Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol. 2011, 29:26-32. 10.1016\/j.tibtech.2010.09.007","journal-title":"Trends Biotechnol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2017.00356","article-title":"Perspective insights into disease progression, diagnostics, and therapeutic approaches in Alzheimer's disease: a judicious update","volume":"9","author":"Jan AT","year":"2017","unstructured":"Jan AT, Azam M, Rahman S, et al.. Perspective insights into disease progression, diagnostics, and therapeutic approaches in Alzheimer's disease: a judicious update. Front Aging Neurosci. 2017, 9:356. 10.3389\/fnagi.2017.00356","journal-title":"Front Aging Neurosci"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2019.00254","article-title":"Role of neurofilament light chain as a potential biomarker for Alzheimer's disease: a correlative meta-analysis","volume":"11","author":"Jin M","year":"2019","unstructured":"Jin M, Cao L, Dai YP. Role of neurofilament light chain as a potential biomarker for Alzheimer's disease: a correlative meta-analysis. Front Aging Neurosci. 2019, 11:254. 10.3389\/fnagi.2019.00254","journal-title":"Front Aging Neurosci"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000904","article-title":"Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease","volume":"34","author":"Leuzy A","year":"2021","unstructured":"Leuzy A, Cullen NC, Mattsson-Carlgren N, Hansson O. Current advances in plasma and cerebrospinal fluid biomarkers in Alzheimer's disease. Curr Opin Neurol. 2021, 34:266-74. 10.1097\/WCO.0000000000000904","journal-title":"Curr Opin Neurol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-230799","article-title":"The associations of phosphorylated Tau 181 and Tau 231 levels in plasma and cerebrospinal fluid with cognitive function in Alzheimer's disease: a systematic review and meta-analysis","volume":"98","author":"Li Z","year":"2024","unstructured":"Li Z, Fan Z, Zhang Q. The associations of phosphorylated Tau 181 and Tau 231 levels in plasma and cerebrospinal fluid with cognitive function in Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis. 2024, 98:13-32. 10.3233\/JAD-230799","journal-title":"J Alzheimers Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10040850","article-title":"Development of Alzheimer's disease biomarkers: from CSF- to blood-based biomarkers","volume":"10","author":"Mankhong S","year":"2022","unstructured":"Mankhong S, Kim S, Lee S, Kwak HB, Park DH, Joa KL, Kang JH. Development of Alzheimer's disease biomarkers: from CSF- to blood-based biomarkers. Biomedicines. 2022, 10:10.3390\/biomedicines10040850","journal-title":"Biomedicines"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1021\/acschemneuro.3c00641","article-title":"Blood biomarkers in Alzheimer's disease","volume":"14","author":"Mandal PK","year":"2023","unstructured":"Mandal PK, Maroon JC, Garg A, et al.. Blood biomarkers in Alzheimer's disease. ACS Chem Neurosci. 2023, 14:3975-8. 10.1021\/acschemneuro.3c00641","journal-title":"ACS Chem Neurosci"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2024.148812","article-title":"Present and future of blood-based biomarkers of Alzheimer's disease: beyond the classics","volume":"1830","author":"Mantellatto Grigoli M","year":"2024","unstructured":"Mantellatto Grigoli M, Pelegrini LN, Whelan R, Cominetti MR. Present and future of blood-based biomarkers of Alzheimer's disease: beyond the classics. Brain Res. 2024, 1830:148812. 10.1016\/j.brainres.2024.148812","journal-title":"Brain Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10071713","article-title":"A systematic review and meta-analysis of cerebrospinal fluid amyloid and Tau levels identifies mild cognitive impairment patients progressing to Alzheimer's disease","volume":"10","author":"Ma Y","year":"2022","unstructured":"Ma Y, Brettschneider J, Collingwood JF. A systematic review and meta-analysis of cerebrospinal fluid amyloid and Tau levels identifies mild cognitive impairment patients progressing to Alzheimer's disease. Biomedicines. 2022, 10:10.3390\/biomedicines10071713","journal-title":"Biomedicines"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21145007","article-title":"Serum Tau proteins as potential biomarkers for the assessment of Alzheimer's disease progression","volume":"21","author":"Nam E","year":"2020","unstructured":"Nam E, Lee YB, Moon C, Chang KA. Serum Tau proteins as potential biomarkers for the assessment of Alzheimer's disease progression. Int J Mol Sci. 2020, 21:10.3390\/ijms21145007","journal-title":"Int J Mol Sci"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9061673","article-title":"Diagnostic biomarkers for Alzheimer's disease using non-invasive specimens","volume":"9","author":"Paraskevaidi M","year":"2020","unstructured":"Paraskevaidi M, Allsop D, Karim S, Martin FL, Crean S. Diagnostic biomarkers for Alzheimer's disease using non-invasive specimens. J Clin Med. 2020, 9:10.3390\/jcm9061673","journal-title":"J Clin Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3988\/jcn.2022.18.4.401","article-title":"Promising blood biomarkers for clinical use in Alzheimer's disease: a focused update","volume":"18","author":"Park SA","year":"2022","unstructured":"Park SA, Jang YJ, Kim MK, Lee SM, Moon SY. Promising blood biomarkers for clinical use in Alzheimer's disease: a focused update. J Clin Neurol. 2022, 18:401-9. 10.3988\/jcn.2022.18.4.401","journal-title":"J Clin Neurol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2023.1297984","article-title":"Ketone bodies mediate alterations in brain energy metabolism and biomarkers of Alzheimer's disease","volume":"17","author":"Ramezani M","year":"2023","unstructured":"Ramezani M, Fernando M, Eslick S, et al.. Ketone bodies mediate alterations in brain energy metabolism and biomarkers of Alzheimer's disease. Front Neurosci. 2023, 17:1297984. 10.3389\/fnins.2023.1297984","journal-title":"Front Neurosci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1177\/2211068214559979","article-title":"Biomarkers in the diagnosis and prognosis of Alzheimer's disease","volume":"20","author":"Schaffer C","year":"2015","unstructured":"Schaffer C, Sarad N, DeCrumpe A, et al.. Biomarkers in the diagnosis and prognosis of Alzheimer's disease. J Lab Autom. 2015, 20:589-600. 10.1177\/2211068214559979","journal-title":"J Lab Autom"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glz005","article-title":"Platelet amyloid-\u03b2 protein precursor (A\u03b2PP) ratio and phosphorylated Tau as promising indicators for early Alzheimer's disease","volume":"75","author":"Shi Y","year":"2020","unstructured":"Shi Y, Gu L, Wang Q, et al.. Platelet amyloid-\u03b2 protein precursor (A\u03b2PP) ratio and phosphorylated Tau as promising indicators for early Alzheimer's disease. J Gerontol A Biol Sci Med Sci. 2020, 75:664-70. 10.1093\/gerona\/glz005","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acc.2023.05.001","article-title":"Phosphorylated tau in Alzheimer's disease","volume":"116","author":"Telser J","year":"2023","unstructured":"Telser J, Grossmann K, Wohlwend N, Risch L, Saely CH, Werner P. Phosphorylated tau in Alzheimer's disease. Adv Clin Chem. 2023, 116:31-111. 10.1016\/bs.acc.2023.05.001","journal-title":"Adv Clin Chem"},{"key":"ref28","article-title":"Blood phosphorylated tau in the diagnosis of Alzheimer's disease: a systematic review and meta-analysis","author":"Therriault J","year":"2023","unstructured":"Therriault J, Macedo A, Rosa-Neto P, et al.. Blood phosphorylated tau in the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Prospero. 2023,","journal-title":"Prospero"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/hvad135","article-title":"Recommendations for setting a criterion and assessing commutability of sample materials used in external quality assessment\/proficiency testing schemes","volume":"69","author":"Sandberg S","year":"2023","unstructured":"Sandberg S, Fauskanger P, Johansen JV, et al.. Recommendations for setting a criterion and assessing commutability of sample materials used in external quality assessment\/proficiency testing schemes. Clin Chem. 2023, 69:1227-37. 10.1093\/clinchem\/hvad135","journal-title":"Clin Chem"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1035797","article-title":"Alteration of plasma tau protein and the risk of developing Alzheimer's disease: A systematic review and meta-analysis","volume":"15","author":"Wang X","year":"2024","unstructured":"Wang X, Sun Z, Xu Z, et al.. Alteration of plasma tau protein and the risk of developing Alzheimer's disease: A systematic review and meta-analysis. Front Aging Neurosci. 2024, 15:1035797. 10.3389\/fnagi.2023.1035797","journal-title":"Front Aging Neurosci"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24533","article-title":"Hsa_circ_0005100 regulates tumorigenicity of colorectal carcinoma via miR-145-5p\/MACC1 axis","volume":"36","author":"Zhang T","year":"2022","unstructured":"Zhang T, Yu S, Zhao S. Hsa_circ_0005100 regulates tumorigenicity of colorectal carcinoma via miR-145-5p\/MACC1 axis. J Clin Lab Anal. 2022, 36:e24533. 10.1002\/jcla.24533","journal-title":"J Clin Lab Anal"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.3390\/cells12081184","article-title":"Utility of blood-based tau biomarkers for mild cognitive impairment and Alzheimer's disease: systematic review and meta-analysis","volume":"12","author":"Zabala-Findlay A","year":"2023","unstructured":"Zabala-Findlay A, Penny LK, Lofthouse RA, et al.. Utility of blood-based tau biomarkers for mild cognitive impairment and Alzheimer's disease: systematic review and meta-analysis. Cells. 2023, 12:10.3390\/cells12081184","journal-title":"Cells"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.14336\/AD.2023.0427","article-title":"Plasma amyloid-\u03b2 and tau as biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis","volume":"14","author":"Zhang L","year":"2023","unstructured":"Zhang L, Xu Y, Chen H, Zhang Y, Zheng X, Li Y. Plasma amyloid-\u03b2 and tau as biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Aging Dis. 2023, 14:1023-37. 10.14336\/AD.2023.0427","journal-title":"Aging Dis"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0755-1","article-title":"Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia","volume":"26","author":"Janelidze S","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S, et al.. Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia. Nat Med. 2020, 26:379-86. 10.1038\/s41591-020-0755-1","journal-title":"Nat Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders","volume":"324","author":"Palmqvist S","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT, et al.. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020, 324:772-81. 10.1001\/jama.2020.12134","journal-title":"JAMA"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200861","article-title":"Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease","volume":"217","author":"Barth\u00e9lemy NR","year":"2020","unstructured":"Barth\u00e9lemy NR, Horie K, Sato C, Bateman RJ. Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer's disease. J Exp Med. 2020, 217:10.1084\/jem.20200861","journal-title":"J Exp Med"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23746-0","article-title":"Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations","volume":"12","author":"Cullen NC","year":"2021","unstructured":"Cullen NC, Leuzy A, Janelidze S, et al.. Plasma biomarkers of Alzheimer's disease improve prediction of cognitive decline in cognitively unimpaired elderly populations. Nat Commun. 2021, 12:3555. 10.1038\/s41467-021-23746-0","journal-title":"Nat Commun"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30071-5","article-title":"Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts","volume":"19","author":"Karikari TK","year":"2022","unstructured":"Karikari TK, Pascoal TA, Ashton NJ, et al.. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol. 2022, 19:422-33. 10.1016\/S1474-4422(20)30071-5","journal-title":"Lancet Neurol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/343398-blood-based--amyloid-and-phosphorylated-tau-p-tau-biomarkers-in-alzheimers-disease-a-systematic-review-of-their-diagnostic-potential","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T15:28:13Z","timestamp":1740842893000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/343398-blood-based--amyloid-and-phosphorylated-tau-p-tau-biomarkers-in-alzheimers-disease-a-systematic-review-of-their-diagnostic-potential"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.79881","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,1]]}}}